BPC June 23 update

11 Biotech Stock events to watch next week; Biotech week in review

Weekly watchlist

 Last week saw a steady stream of price moving biotech news and the last week of the first half of 2018 promises more of the same. An unusually large number of catalysts are still slated for release this month. It is not uncommon for companies to miss their time guidance by around a week so let’s see which companies meet their timelines.

First, news from the week that was:

Heron Therapeutics, Inc. (NASDAQ: HRTX) shares surged Thursday to close up 30% to $39.95 following news that its Phase 2b trial of HTX-011 in total knee arthroplasty and breast augmentation achieved the primary endpoints in both trials. 

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares closed Tuesday up 37% to $143.93 following the release of positive preliminary data from its Phase 1/2a gene therapy clinical trial assessing micro-Dystrophin gene therapy in three patients with Duchenne muscular dystrophy (DMD). 

Anika Therapeutics, Inc. (NASDAQ: ANIK) shares closed Wednesday down 38% to $28.77 following news that its Phase 3 CINGAL trial in patients with osteoarthritis in the knee did not meet its primary endpoint.

ObsEva SA (NASDAQ: OBSV) announced Monday that its Phase 2b Edelweiss trial of linzagolix for the treatment of endometriosis-associated pain met the primary endpoint for the three top doses. Shares closed up 23% to $17.87.

PTC Therapeutics (NASDAQ: PTCT) shares closed Monday up 28% to $47.88 following the presentation of data from its Phase 1 trial of risdiplam for the treatment of spinal muscular atrophy (SMA) but sold off Tuesday following the DMD data from Sarepta.

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that it was issued a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for IDP-118 lotion in the treatment of plaque psoriasis. Shares closed Monday down 12% to $23.56.

Catalyst Biosciences, Inc. (Nasdaq:CBIO) shares slumped Monday to close down 64% to $9.11 following an update of its Phase 1/2 trial of CB 2679d/ISU304 for the treatment of severe hemophilia B that noted the presence of a neutralizing antibodies in patients' blood.

Ziopharm Oncology, Inc. (Nasdaq:ZIOP) announced Monday the FDA has placed on clinical hold its Sleeping Beauty Phase 1 trial to evaluate CD19-specific CAR-T therapies. Shares closed down 18% to $3.51.

11 biotech stock events to watch for the final week of June:

Drug Price Stage Catalyst Market Cap

ALKS – Alkermes plc
ARISTADA INITIO(aripiprazole lauroxil)

+0.07  +0%
Approved FDA approval announced July 2, 2018.
$5 billion

CTIC – CTI BioPharma Corp.

-0.04  -1%
PDUFA priority review PDUFA date under priority review November 30, 2021.
$249.6 million

GBT – Global Blood Therapeutics Inc.
OXBRYTA (voxelotor)
Sickle cell disease

-0.14  0%
Approved FDA Approval announced November 25, 2019.
$1.9 billion

JAZZ – Jazz Pharmaceuticals plc
EPIDIOLEX (cannabidiol)
Dravet Syndrome and Lennox-Gastaut syndrome

+0.96  +1%
Approved Approval announced June 25, 2018.
$8.9 billion

LLY – Eli Lilly and Company
QBREXZA (glycopyrronium)
Primary axillary hyperhidrosis

+1.53  +1%
Approved Approval announced June 29, 2018.
$232.2 billion

MACK – Merrimack Pharmaceuticals Inc.
Cancer - front line pancreatic cancer

-0.18  -4%
Phase 2 Phase 2 data released June 25, 2018 - endpoints not met.
$59.5 million